Search in:

Advanced search

Expert Opinion on Biological Therapy Volume 23, 2023 - Issue 8: Biosimilars

Submit an article Journal homepage

325

Views

CrossRef citations to date

Altmetric

Original Research

Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)

Ashish Sharmaa Lotus Eye Hospital and Institute, Coimbatore, IndiaCorrespondence[email protected]

https://orcid.org/0000-0002-8550-9791 View further author information

Frank G Holzb Department of Ophthalmology, University of Bonn, Bonn, GermanyView further author information

Carl D Regilloc The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USAView further author information

K Bailey Freundd Vitreous Retina Macula Consultants of New York, New York, USA;e Department of Ophthalmology, NYU Grossman School of Medicine, New York, NY, USAView further author information

David Sarraff Stein Eye Institute, UCLA, Los Angeles, CA, USA;g Department of Ophthalmology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USAView further author information

Arshad M. Khananih Sierra Eye Associates, Reno, NV, USA and The University of Nevada, Reno School of Medicine, Reno, NV, USA

https://orcid.org/0000-0001-8928-5599 View further author information

Caroline Baumali Tufts University School of Medicine, New England Eye Center, Boston, MassachusettsView further author information

Nancy Holekampj Pepose Vision Institute, St. Louis, Missouri, USA

https://orcid.org/0000-0001-7850-8515 View further author information

Ramin Tadayonik Université Paris Cité, AP-HP, Lariboisière, St Louis and Fondation Adolphe de Rothschild hospitals, Paris, FranceView further author information

Nilesh Kumarl Madhavi Netralaya, Ara, India

https://orcid.org/0000-0002-7439-2081 View further author information

Nikulaa Parachurim Department of Vitreoretina, Sankara Eye Hospital, Coimbatore, IndiaView further author information

Baruch D Kuppermannn Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USAView further author information

& International Retina Biosimilar Study Group (Inter BIOS Group) show allInternational Retina Biosimilar Study Group (Inter BIOS Group),

Francesco BandelloView further author information

Giuseppe QuerquesView further author information

Anat LoewensteinView further author information

Şengül ÖzdekView further author information

Kourous RezaiView further author information

Kodjikian LaurentView further author information

Alper BilgicView further author information

Paolo LanzettaView further author information

Dinah ZurView further author information

Nicolas YannuzziView further author information

Giulia CorradettiView further author information

Peter KaiserView further author information

Assaf HilelyView further author information

David BoyerView further author information

Aleksandra RachitskayaView further author information

Usha ChakravarthyView further author information

Maximilian WintergerstView further author information

Valentina SaraoView further author information

Barbara ParoliniView further author information

Prithvi MruthyunjayaView further author information

Quan Dong NguyenView further author information

Diana DOView further author information

Pearse A KeaneView further author information

Tarek HassanView further author information

Jayanth SridharView further author information

David EichenbaumView further author information

Dilraj GrewalView further author information

Martin SplitzerView further author information

show all

Pages 851-859 | Received 23 Sep 2022, Accepted 31 Jan 2023, Published online: 19 Feb 2023

Cite this article
https://doi.org/10.1080/14712598.2023.2176218
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Sharma A, Kumar N, Parachuri N, et al. Biosimilars for retinal diseases: an update. Am J Ophthalmol. 2021;224:36–42.
PubMed Web of Science ®Google Scholar
FDA approves Samsung bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) https://investors.biogen.com/news-releases/news-release-details/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11. September 07, 2022
Google Scholar
Ranibizumab Biosimilar (Byooviz) gains EU marketing authorization. https://www.centerforbiosimilars.com/view/samsung-bioepis-byooviz-gains-ema-marketing-authorization. cited 2022 Sept 07
Google Scholar
FDA approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis® for all five indications, with 12 months of interchangeability exclusivity. https://investors.coherus.com/news-releases/news-release-details/fda-approves-coherus-cimerlitm-ranibizumab-eqrn-first-and-only. Cited 2022 Sept 07
Google Scholar
European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis. https://www.formycon.com/en/press-release/european-commission-approves-fyb201-ranivisio1-ranivisio-ranibizumab-a-biosimilar-to-lucentis2/. Cited 2022 Sep 07
Google Scholar
Retina anti-VEGF biosimilars: how to prepare for the coming wave https://www.syneoshealth.com/insights-hub/retina-anti-vegf-biosimilars-how-prepare-coming-wave. Cited 2022 Sep 07
Google Scholar
Mielke J, Jilma B, Koenig F, et al. Clinical trials for authorized biosimilars in the European Union: a systematic review. Br J Clin Pharmacol. 2016;82(6):1444–1457.
PubMed Web of Science ®Google Scholar
Berndt ER, Aitken ML. Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-hatch legislation. Int J Econ Bus. 2011;18(2):177–201.
Google Scholar
Sharma A, Kuppermann BD. Biosimilars for retinal diseases: understanding the phase 3 clinical trial design. Ophthalmology. 2022;129(1):65–66.
PubMed Web of Science ®Google Scholar
Sharma A, Kumar N, Parachuri N. Biosimilar Ranibizumab (SB11) vs reference Ranibizumab—Diving deeper for safety and efficacy. JAMA Ophthalmology. 2021;139(6):677–679.
PubMed Web of Science ®Google Scholar
Sharma A, Hafeez Faridi M, Kumar N, et al. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye (Lond). 2020;34(6):1008–1009.
PubMed Web of Science ®Google Scholar
Sharma A, Kumar N, Kuppermann BD, et al. Ophthalmic biosimilars and biologics-role of endotoxins. Eye (Lond). 2020;34(4):614–615.
PubMed Web of Science ®Google Scholar
Sharma A, Kumar N, Kuppermann BD, et al. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br J Ophthalmol. 2020;104(1):2–7.
PubMed Web of Science ®Google Scholar
Sharma A, Kumar N, Kuppermann BD, et al. Ophthalmic biosimilars: lessons from India. Indian J Ophthalmol. 2019;67:1384–1385.
PubMed Web of Science ®Google Scholar
Sharma A, Kumar N, Bandello F, et al. Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye (Lond). 2020;34(6):1006–1007.
PubMed Web of Science ®Google Scholar
Opinion: is the ophthalmology market ready to embrace biosimilars? https://www.centerforbiosimilars.com/view/is-the-ophthalmology-market-ready-to-embrace-biosimilars-. Cited 2022 Jan 18
Google Scholar
O’Callaghan J, Bermingham M, Leonard M, et al. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: a survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol. 2017;88:252–261.
PubMed Web of Science ®Google Scholar
Cohen H, Beydoun D, Chien D, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2016;33:2160–2172.
PubMed Web of Science ®Google Scholar
Ranibizumab Biosimilar FYB201 provides similar efficacy, safety in phase 3 trial. https://www.hcplive.com/view/ranibizumab-biosimilar-fyb201-similar-efficacy-safety-phase-3-trial. Cited 2022 Jan 18
Google Scholar
Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India Permission to manufacture and market ranibizumab solution for injection (r-DNA origin) (permission no: MF-35/2015; BULK-36/2015). Manufacturer Intas Pharmaceuticals Limited, Ahmedabad, Gujarat, India. 2013. https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTUzNg==. Cited 2022 Jan 18
Google Scholar
Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis Organization. J Crohns Colitis. 2014;8(11):1548–1550.
PubMed Web of Science ®Google Scholar
Grabowski D, Henderson B, Lam D, et al. Attitudes towards subsequent entry biologics/biosimilars: a survey of Canadian rheumatologists. Clin Rheumatol. 2015;34(8):1427–1433.
PubMed Web of Science ®Google Scholar
Mehr SR, Zimmerman MP. Is a biologic produced 15 years ago a biosimilar of itself today? Am Health Drug Benefits. 2016;9(9):515–518.
PubMed Web of Science ®Google Scholar
Changes to an approved application: biological products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-application-biological-products. Cited 2022 Jan 18
Google Scholar
Barbier L, Ebbers HC, Declerck P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734–755.
PubMed Web of Science ®Google Scholar
Sharma A, Kumar N, Parachuri N, et al. Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians? Eye (Lond). 2022.
Web of Science ®Google Scholar
Outlook therapeutics presents NORSE TWO phase 3 pivotal safety and efficacy data for ONS-5010/LYTENAVA™ (bevacizumab-vikg) at the retina subspecialty day, American Academy of Ophthalmology (AAO) 2021 Annual Conference. https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-presents-norse-two-phase-3-pivotal-safety. Cited 2022 Jan 18
Google Scholar
Sheth JU, Stewart MW, Khatri M, et al. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey. Indian J Ophthalmol. 2021;69(2):352–356.
PubMed Web of Science ®Google Scholar
Biosimilars action plan: balancing innovation and competition. 2018. https://www.fda.gov/media/114574/download. Cited 2022 Jan 18
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date